Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.25 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 84.33 3.66 0.45 13.9 40
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 6.25 GBX

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Investors    Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics (AGY) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Top Posts
Posted at 04/2/2023 08:20 by Allergy Therapeutics Daily Update
Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 6.25p.
Allergy Therapeutics Plc has a 4 week average price of 0p and a 12 week average price of 4.50p.
The 1 year high share price is 26p while the 1 year low share price is currently 4.50p.
There are currently 643,597,146 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Allergy Therapeutics Plc is £40,224,821.63.
Posted at 03/2/2023 17:25 by 1kckeith
The big risk we run is that the company goes private as part of the refinancing, where we are offered a choice of a low price for our shares or to stay locked in to a private entity with little to no say in its running. Even this latter option may only be a possibility if over 10% fail to accept (they fail to get to 90% acceptances). In my more paranoid moments I think the changed provision in the new Articles for selling untraced shareholders' shares is to facilitate a squeeze-out over time.
If they had set out to create favourable preconditions for a take-private they could not have done a better job. Shares suspended, price at an all-time low, company seeking finance with its back to the wall, shareholders powerless. I'm not saying this was planned, but if Llobet and others on the board end up in the new private entity it would not look good.

Posted at 08/12/2022 18:45 by amishp67
I couldn't agree more. I believe that the wording regarding funding was slightly concerning. They have plenty of cash in the bank so why do they need to raise more money. Or are we mistaken because their wording is poor, and that because of the pause in production they are reviewing their working capital cycle to collect cash owed to them quicker..faster sales etc. I think they needed to be more clearer on what they mean exactly.It also makes you think why Directors are not snapping up shares at this price to show their confidence.That being said, I do think that we have to be patient here because if this is successful the share price will reverse and rocket up.There is a small percentage of retail investors in this company. Most are held by the big boys (who are clearly still holding) the volumes are small, it only takes small volumes to push this share price down, which to me means there's nothing to worry about. People who sell now will probably end up buying back once things progress.I think we good..just need to be patient (don't look at the price) and let's hope for promising progress on the grass and peanut.
Posted at 08/12/2022 16:53 by genises
Thought we had done funding through Southern Fox and ZQ Capita{major shareholder}Who as a shareholder can not be happy with the share price.£7million at 20p
Nice to see the directors buying on the open market at these low prices not ,shows confidence.
Time for a New CEO.

Posted at 08/12/2022 08:16 by wizzkid211
Allergy Therapeutics Plc (LSE)
LSE:AGY



Allergy Therapeutics Share News (AGY)
4
Follow AGYBuySell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
0.00 0.0% 13.25 13.00 13.50 0.00 19:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 84.3 3.7 0.5 29.4 85
Print
Alert
Allergy Therapeutics PLC Key updates on Grass MATA MPL and VLP Peanut
08/12/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 8 December 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 9931I

Allergy Therapeutics PLC

08 December 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics announces key updates on Grass MATA MPL

and VLP Peanut clinical programmes

Update on production and funding

- Innovative short-course grass pollen immunotherapy with best-in-class potential
- If successful, Grass MATA MPL will be the first subcutaneous and aluminium -- free short-course allergy immunotherapy approved in the US

- Topline safety & efficacy data for Grass MATA MPL expected Q4 2023
- Safety, tolerability and efficacy data for VLP peanut expected 2023
8 December 2022 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, t hat aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

Grass MATA MPL incorporates MicroCrystalline Tyrosine ("MCT(R) ") adsorbed allergoids, and the innovative adjuvant Monophosphoryl-lipid A ("MPL"). This innovative technology only requires patients to receive six injections prior to the grass allergy season to be protected.

The pivotal Phase III G306 trial is a multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of Grass MATA MPL. The clinical trial will be conducted in the US and Europe at approximately 120 clinical trial sites. Data readout is planned for Q4 2023.

Previously announced top-line results from the G309 exploratory field trial showed meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season.

In addition, the first subjects have been screened and are poised to receive the Group's innovative, short-course peanut allergy vaccine candidate, VLP Peanut in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy. Plans remain on track for data in 2023.

Update on production and funding

Further to the announcement on the 28(th) October, work is continuing on cost control and tight capital management following the impact of the pause in production. This includes reviewing all funding options and managing the working capital of the Group.

Manuel Llobet, CEO of Allergy Therapeutics, commented: " The start of our pivotal Phase III G306 trial investigating the efficacy and safety of our Grass MATA MPL marks the culmination of our efforts to bring this innovative treatment to millions of patients affected by grass allergies in both the US and Europe. We were encouraged by the results of our short-course grass pollen immunotherapy in the highly successful G309 exploratory field trial and look forward to advancing the development of this innovative treatment. The start of the VLP Peanut PROTECT trial is a significant milestone and a testament to the hard work of the Allergy Therapeutics team, developing innovative approaches that have the potential to transform the way we treat and manage allergies."

More information about the Phase III G306 Grass MATA MPL trial can be found on ClinicalTrials.gov under the identifier NCT05540717 .

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduces the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

Posted at 06/12/2022 07:20 by jimmyloser
With the share price on its backside and their recent investments, along with their significant shareholding's, this mornings news should come as no surprise. For me it brings a glimmer of hope. Change afoot?Impo
Posted at 10/11/2022 09:30 by jpuff
It's been dead money for years, no divi, no share price appreciation. What's not to like!
Posted at 08/11/2022 18:19 by jimmyloser
When the company said something about peanuts, I hadn't realised that they were referring to the share price. Oh, my days!
Posted at 28/10/2022 06:58 by wizzkid211
Allergy Therapeutics PLC Allergy to resume UK manufacturing production
28/10/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Friday 28 October 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 4690E

Allergy Therapeutics PLC

28 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics to resume UK manufacturing production in mid-November

28(th) October 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergen immunotherapy, today announces that it will resume production at the Freeman facility, part of its Worthing, UK manufacturing site, on 14(th) November.

The Group announced a short-term voluntary pause in production following an internal review of its current operating processes. This pause was part of the Group's previously communicated ongoing programme to improve the robustness of its quality systems and build capacity across its manufacturing facilities but was accelerated when it became clear that the capacity was unable to cope with the commercial demand.

The pause in manufacturing occurred during a period of peak production prior to the start of the pollen season in the spring. As a consequence, whilst it is too early to determine the exact impact, it is currently estimated that revenue will be between approximately 13% and 18% lower than market expectations of circa GBP80m at current exchange rates for the year ended 30 June 2023. Business expenses for the same period are currently expected to reduce by around GBP3m.

Work is continuing to further minimise the impact through cost control and tight working capital management and delay in non-critical capital spend.

At the expected reduced levels of underlying profit, excluding research and development costs, the terms of the NatWest revolving credit facility would not allow use of the facility.

Manuel Llobet, CEO at Allergy Therapeutics , stated: "We took the difficult decision to temporarily pause production at the Freeman facility to continue delivering the highest standards of quality systems. We are now pleased to have a clear timeline to resume our UK manufacturing activities."

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

Posted at 17/10/2022 14:04 by wizzkid211
RNS Number : 1398D

Allergy Therapeutics PLC

17 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL", the "Company" or the "Group")

Result of GM

17 October 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, announces that at the General Meeting ("GM") held today all resolutions were duly passed.

Accordingly, the Company has conditionally raised total gross proceeds of approximately GBP17,000,000 million in aggregate (before expenses) through the Subscription and Debt Financing as described in the announcement date 29 September 2022. The Subscription and Debt Financing remain conditional on Admission.

Admission

An application has been made for 35,000,000 New Ordinary Shares to be admitted to trading on AIM. Admission of the New Ordinary Shares are expected to occur at 8.00 a.m. on, or around, 19 October 2022. The New Ordinary Shares will rank pari passu with the Existing Ordinary Shares.

Total Voting Rights

Following Admission of the New Ordinary Shares, the Company's issued ordinary share capital will consist of 679,104,621 Ordinary Shares, carrying one vote each. The Company does not currently hold any shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 679,104,621. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

Save as defined herein, capitalised terms have the same meaning as in the Company's Subscription and Debt Financing announcement made by the Company on 29 September 2022.

- ENDS -

Posted at 29/9/2022 06:04 by wizzkid211
Allergy Therapeutics PLC Unaudited Preliminary Results 2022
29/09/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 29 September 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 0796B

Allergy Therapeutics PLC

29 September 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Unaudited Preliminary Results for the Year ended 30 June 2022

- Phase I VLP Peanut PROTECT trial, incorporating ground-breaking VLP technology, commencing shortly

- Highly successful exploratory field trial for Grass MATA MPL, achieved 40% improvement in combined symptom and medication score compared to placebo, with pivotal Phase III trial on track to start in Q4 2022

- Robust 2022 trading with revenue of GBP72.8m (2021: GBP84.3m) on streamlined portfolio
- Continued growth of key commercial products, Pollinex, Venomil and Acarovac
29 September 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces its unaudited preliminary results for the year ended 30 June 2022.

Highlights (including post-period events)

Financial

- Robust sales of GBP72.8m (2021: GBP84.3m) from commercial portfolio. Strategic streamlining of older products to focus on high value growth products has resulted in a decrease of 14% in actual terms (9%* in constant terms)

- Operating profit pre-R&D of GBP3.4m (2021: GBP16.9m) reflecting portfolio streamlining, COVID-19 headwinds and investment in supply chain

- Strong cash balance of GBP20.5m (2021: GBP40.3m) providing ongoing support for the Group's two key clinical trials

- Full year net loss of GBP13.8m (2021: Net profit of GBP2.9m)
- Announced the fundraise today for GBP7m (before expenses) and loan notes to the value of GBP10m to complete funding of October's Phase I VLP Peanut PROTECT trial, Phase III Grass MATA MPL trial as well as preparations for use of placebo arm of Grass MATA MPL trial to increase safety database and Phase II development of VLP Peanut. Fundraise supported by a number of the Company's largest shareholders.

Operational

- Acceptance by the US FDA of IND application for VLP Peanut with Phase I PROTECT trial in the US due to commence shortly

- Highly successful exploratory field trial for Grass MATA MPL, achieving 40% improvement in combined symptom and medication score compared to placebo

- Continued growth of key commercial products, Pollinex, Venomil and Acarovac, in streamlined portfolio

Manuel Llobet, CEO of Allergy Therapeutics, stated:

"Over the past financial year, we have made significant progress in advancing our clinical pipeline and we are excited to be approaching the start of two key clinical trials in our innovative immunotherapy pipeline. The first-in-human PROTECT trial of our peanut allergy vaccine candidate and the pivotal phase III trial for our grass pollen immunotherapy are significant milestones in our journey to bring these potentially life-changing treatments to patients.

"While market conditions remain challenging for many companies, our leading core European commercial business has been resilient. With a solid cash position and strong, established commercial capabilities that set us apart from solely R&D focused health companies, we are uniquely positioned to create value for our shareholders ."

*Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year-on-year comparison excluding the effects of foreign exchange movements. See table in finance review for an analysis of revenue.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

-S -

Analyst briefing and webcast today

Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Business Innovation, will host a meeting and webcast for analysts and investors at 12pm UK time today. The live webcast can be accessed here . Please contact Consilium Strategic Communications for more details on allergytherapeutics@consilium-comms.com .

For further information, please contact:

Allergy Therapeutics

Allergy Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
AGY
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230205 04:31:56